Last Updated: September 28, 2026

Msd Sub Merck Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MSD SUB MERCK

MSD SUB MERCK has fourteen approved drugs.

There are seventeen US patents protecting MSD SUB MERCK drugs.

Summary for Msd Sub Merck

US Patents:	17
Tradenames:	13
Ingredients:	11
NDAs:	14

Drugs and US Patents for Msd Sub Merck

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET	metformin hydrochloride; sitagliptin phosphate	TABLET;ORAL	022044-002	Mar 30, 2007	AB	RX	Yes	Yes	7,326,708*PED	⤷ Start Trial			Y	⤷ Start Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-002	Dec 19, 2017		RX	Yes	No	8,080,580	⤷ Start Trial	Y	Y		⤷ Start Trial
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	7,326,708*PED	⤷ Start Trial			Y	⤷ Start Trial
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015	AP	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-002	Dec 19, 2017		RX	Yes	No	9,308,204	⤷ Start Trial	Y			⤷ Start Trial
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012	AB	RX	Yes	No	7,326,708*PED	⤷ Start Trial			Y	⤷ Start Trial
Msd Sub Merck	ISENTRESS	raltegravir potassium	POWDER;ORAL	205786-001	Dec 20, 2013		RX	Yes	Yes	7,754,731*PED	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Msd Sub Merck

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006	RE38506	⤷ Start Trial
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,303,661	⤷ Start Trial
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,890,898	⤷ Start Trial
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,635,280	⤷ Start Trial
Msd Sub Merck	INTEGRILIN	eptifibatide	INJECTABLE;INJECTION	020718-001	May 18, 1998	5,968,902	⤷ Start Trial
Msd Sub Merck	INTEGRILIN	eptifibatide	INJECTABLE;INJECTION	020718-001	May 18, 1998	5,807,825	⤷ Start Trial
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015	7,265,099	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for MSD SUB MERCK drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2008-09-30
➤ Subscribe	Injection	0.75 mg/mL, 100 mL vial	➤ Subscribe	2009-06-05
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2011-10-12
➤ Subscribe	Extended-release Capsules	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2012-03-16
➤ Subscribe	Tablets	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Injection	2 mg/mL, 100 mL vial	➤ Subscribe	2008-12-18
➤ Subscribe	Injection	1 g/vial	➤ Subscribe	2013-06-20
➤ Subscribe	Ophthalmic Solution	2%	➤ Subscribe	2005-10-11
➤ Subscribe	Extended-release Tablets	100 mg/1000 mg	➤ Subscribe	2012-10-22

International Patents for Msd Sub Merck Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Israel	173846	⤷ Start Trial
Norway	20092714	⤷ Start Trial
Panama	8840801	⤷ Start Trial
South Korea	100884500	⤷ Start Trial
Brazil	PI0916235	⤷ Start Trial
European Patent Office	1259550	⤷ Start Trial
Canada	2588398	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Msd Sub Merck Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2310095	CR 2016 00070	Denmark	⤷ Start Trial	PRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
1441735	0890018-5	Sweden	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR
1506211	179 5017-2014	Slovakia	⤷ Start Trial	PRODUCT NAME: KOMBINACIA DAPAGLIFLOZINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI A METFORMINU ALEBO JEHO FARMACEUTICKY PRIJATELNYCH SOLI; REGISTRATION NO/DATE: EU/1/13/900/001 - EU/1/13/900/012 20140116
2310095	132017000002002	Italy	⤷ Start Trial	PRODUCT NAME: GRAZOPREVIR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZEPATIER); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1119, 20160726
1261586	C300524	Netherlands	⤷ Start Trial	PRODUCT NAME: COMBINATIE VAN SAXAGLIPTINE EN METFORMINE, DESGEWENST IN DE VORM VAN FARMACEUTISCH AANVAARDBARE AFGELEIDEN DAARVAN; NAT. REGISTRATION NO/DATE: EU/1/11/731/001-012 20111124; FIRST REGISTRATION:
1441735	SZ 30/2008	Austria	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR ODER DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE DAS KALIUMSALZ
1259550	SPC031/2008	Ireland	⤷ Start Trial	SPC031/2008: 20090428, EXPIRES: 20230724
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.